Please assess the completion status of the following clinical trial:

Trial Title: Detecting an Early Response to Donepezil With Measures of Visual Attention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of Alzheimer's Disease~* Mini Mental State Examination score \>15 / 30~* Can swallow pills~Exclusion Criteria:~* No other dementia due to Parkinson's disease, Lewy Body dementia, Normal Pressure Hydrocephalus, Fronto-temporal dementia, or prominent cerebral vascular accident~* No prior or concurrent use of cholinesterase inhibitors~* No prior or concurrent use of memantine hydrochloride~* No other concurrent anticholinergic treatments

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Drug (Type: EXPERIMENTAL): Participants in the Drug group received oral 5mg of Donepezil Hydrochloride daily for 6 months. The Drug group was assessed at baseline, after approximately 6 weeks and after 6 months of treatment. The baseline to 6 weeks phase was part of the double-blind, placebo controlled portion of the trial.
- Placebo (Type: PLACEBO_COMPARATOR): Participants in the placebo group first received oral administration of a placebo pill for approximately 6 weeks. After that initial interval, the study was unblinded and participants in the placebo group then received 5mg of donepezil hydrochloride treatment for 6 months.~The Placebo group was evaluated at baseline, after 6 weeks of placebo, after 6 weeks of donepezil hydrochloride drug treatment, and 6 months of donepezil hydrochloride treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).